Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. by Ahmad, T et al.
European Journal of Heart Failure (2019) 21, 1064–1078 REVIEW
doi:10.1002/ejhf.1557
Why has positive inotropy failed in chronic
heart failure? Lessons from prior
inotrope trials
Tariq Ahmad1,2*, P. Elliott Miller1, Megan McCullough1, Nihar R. Desai1,2,
Ralph Riello1, Mitchell Psotka3, Michael Böhm4, Larry A. Allen5, John R. Teerlink6,
Giuseppe M.C. Rosano7, and Joann Lindenfeld8
1Section of Cardiovascular Medicine, New Haven, CT, USA; 2Center for Outcome Research & Evaluation (CORE), Yale University School of Medicine, New Haven, CT, USA;
3Inova Heart & Vascular Institute, Falls Church, VA, USA; 4Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany; 5Division of Cardiology, School
of Medicine, University of Colorado, Aurora, CO, USA; 6San Francisco Veterans Affairs Medical Center, University of California San Francisco, San Francisco, CA, USA;
7Cardiovascular and Cell Sciences Research Institute, St George’s University of London, London, UK; and 8Vanderbilt Heart and Vascular Institute, Nashville, TN, USA
Received 9 March 2019; revised 19 June 2019; accepted 21 June 2019 ; online publish-ahead-of-print 13 August 2019
Current pharmacological therapies for heart failure with reduced ejection fraction are largely either repurposed anti-hypertensives that blunt
overactivation of the neurohormonal system or diuretics that decrease congestion. However, they do not address the symptoms of heart
failure that result from reductions in cardiac output and reserve. Over the last few decades, numerous attempts have been made to develop
and test positive cardiac inotropes that improve cardiac haemodynamics. However, definitive clinical trials have failed to show a survival
benefit. As a result, no positive inotrope is currently approved for long-term use in heart failure. The focus of this state-of-the-art review
is to revisit prior clinical trials and to understand the causes for their findings. Using the learnings from those experiences, we propose a
framework for future trials of such agents that maximizes their potential for success. This includes enriching the trials with patients who
are most likely to derive benefit, using biomarkers and imaging in trial design and execution, evaluating efficacy based on a wider range of
intermediate phenotypes, and collecting detailed data on functional status and quality of life. With a rapidly growing population of patients
with advanced heart failure, the epidemiologic insignificance of heart transplantation as a therapeutic intervention, and both the cost and
morbidity associated with ventricular assist devices, there is an enormous potential for positive inotropic therapies to impact the outcomes
that matter most to patients.
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What is an inotrope?
In the reductionist’s view of the cardiovascular system, the prin-
cipal function of the heart is to pump blood, and heart failure
is synonymous with pump failure. Indeed, the modalities used
historically — and at present — to describe and quantify heart
failure have placed a large degree of emphasis on measuring
contractile function of the left ventricle, the genesis of which can
be traced at least as far back to the classic physiology experiments
by Otto Frank and Earnest Starling.1–3 The implication has been a
persistent focus on developing therapies that augment left ventric-
ular contractility, collectively referred to as cardiac ‘inotropes’.
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.. The word ‘inotrope’ originates from the Greek inos (fibre) and
trope (turning or moving) and describes therapies that increase
the force of cardiac contractions. While the strict definition of an
inotrope may be both nuanced and unsettled, for the purposes of
this review, we will focus on synthetic therapeutics that act directly
on myocardial cells to increase cardiac contractility and thereby
improve cardiac haemodynamics. We will sidestep a discussion of
digoxin, which continues to be used frequently for the clinical man-
agement of heart failure and has a storied history of investigation
worthy of a separate manuscript.4 We will focus only on patients
with chronic heart failure with ‘reduced ejection fraction’, where
the primary defect is felt to be pump dysfunction, since these are
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the patients for whom inotropes have been developed to date and
will likely be developed in the future.
The purpose of this manuscript is to critically review prior
attempts at developing synthetic positive cardiac inotropes for
the chronically failing heart with reduced left ventricular ejection
fraction (LVEF) — not acute decompensated heart failure with
shock — and to explore the various reasons why they failed
in their efforts to improve clinical outcomes. We will examine
how these prior failures might instruct future development of
effective therapies for this high-risk, medically vulnerable, and
rapidly growing patient population.
Basic mechanisms of cardiac
contractility
The purpose of inotropic interventions in heart failure is to
increase the muscular contractile force of the myocardium.5
Current approaches to increasing contractility are accomplished
primarily through increasing the influx of calcium or maintaining
higher calcium levels in the cytosol of cardiac myocytes during
an action potential. Much of the mechanistic data in this realm
is based on animal models. Contraction occurs in several ways
(Figure 1). First, catecholamines increase contractile force largely
via the 𝛽-adrenoceptor-adenylyl cyclase system.6 Through protein
kinase A, the 𝛽-adrenoceptor system phosphorylates L-type cal-
cium channels to increase calcium influx and ryanodine receptors
to increase sarcoplasmic reticulum calcium release, resulting
in activation of actomyosin cross-bridges. Phosphorylation of
phospholamban accelerates accumulation of calcium. In addition,
relaxation is supported by phosphorylation of troponin I due
to reduced calcium sensitivity of troponin C (positive lusitropy).
Length-dependent activation of cross-bridges — the so-called
‘Frank–Starling mechanism’ — plays a role along with contrac-
tion frequency-dependent activation of contractile force, where
increasing heart rate causes more calcium to enter the cardiomy-
ocyte for release during the next contraction. At the cross-bridge
level, cyclic adenosine monophosphate (cAMP)-mediated increase
in contractility reduces the attachment time of the individual
cross-bridge. As a result, this cAMP-mediated inotropy increases
the rate of force development and rate of relaxation, potentially
at the expense of ‘energetic efficiency’.
The impact of these molecular changes occurs at the level of the
smallest force-producing unit, the actomyosin cross-bridge. Dur-
ing a cross-bridge cycle, the myosin head attaches to actin, rotates
to produce force, and maintains during the ‘on-time’. This effect
is dependent upon the availability of high energy phosphates that
are hydrolysed during this process. Thereafter, the cross-bridge
detaches again to enter its non-force-producing state for the dura-
tion of the ‘off-time’. The contractile force depends on the number
of cross-bridges attached per unit of time. These cross-bridges are
activated by calcium binding to troponin C with the subsequent
conformational changes of tropomyosin and troponin I to facili-
tate actomyosin interaction. The muscle relaxes when calcium is
pumped back into the sarcoplasmic reticulum by the sarcoplas-
mic reticulum calcium pump (SERCA) and transported outside ..
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.. the cell by the sodium–calcium exchanger, a process that is also
dependent on cellular metabolism. On the level of the actomyosin
cross-bridge, inotropy relies largely on: (i) the amount of calcium
available to bind to troponin C, (ii) the calcium affinity of troponin
C, and (iii) the duration of the force-producing state with availability
of high energy phosphates.
A brief history of inotropic agents
and their impact on surrogate
endpoints
Within the syndrome of heart failure with reduced ejection frac-
tion, there is a growing subgroup of patients who have worsening
disease that is typified by signs and symptoms of hypotension and
hypoperfusion.7 These patients, characterized as having stage D
heart failure, are increasingly unable to tolerate neurohormonal
blockade, and their options are limited to cardiac transplantation,
ventricular assist devices, inotropic infusions, or hospice.8 The
primary pathology in these patients is thought to be a decrease
in cardiac contractility and the development of positive inotropes
has been aimed at correcting this defect: almost every inotropic
agent that survived to clinical evaluation has shared a common
therapeutic goal: to increase the amplitude of cytosolic calcium
transients or sensitivity of the sarcomere, thus increasing the force
of contraction.
The first of these was dobutamine, created in 1975 by modifying
the chemical structure of isoproterenol to reduce its chronotropic,
arrhythmogenic, and vascular side effects. This increased its action
on the 𝛽1 cardiac receptors whilst minimizing the impact on the 𝛼1
and 𝛽2 vascular receptors. Mechanistically, dobutamine appeared
to provide the beneficial aspects of adrenergic signalling in heart
failure while bypassing deleterious peripheral vasoconstriction:
increasing stroke volume and decreasing systemic and pulmonary
vascular resistance and pulmonary capillary wedge pressure.
A string of phosphodiesterase (PDE) inhibitors were subse-
quently developed, including amrinone and followed by milrinone
and enoximone, all of which worked downstream to the 𝛽1 car-
diac adrenergic receptors by inhibiting the enzyme (PDE-3), one
of those role is to catalyse the breakdown of cAMP and leading
to an increased intracellular calcium.9–12 The most prominent of
the PDE inhibitors was milrinone; both its intravenous and oral
forms improved cardiac haemodynamics in heart failure patients.13
Phase 2 clinical trials of other PDE inhibitors, such as amrinone and
enoximone, also improved haemodynamics and exercise capacity in
patients with advanced heart failure.9,14
In the 1980s, an alternate method to increase cardiac contractil-
ity was proposed: to enhance the contractile apparatus’ sensitivity
to calcium.15 Levosimendan, the prototype for this mechanism of
action, binds to troponin C depending on intracellular calcium con-
centrations. Via this mechanism, it increases calcium sensitivity only
during systole without impairing diastolic relaxation.16 Levosimen-
dan also has PDE inhibitors and ATP sensitive K+ channel activating
effects that result in potent peripheral vasodilatation. In patients
with heart failure, levosimendan increased cardiac output, reduced
pulmonary capillary wedge pressures, and improved symptoms.17,18
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 (A) Normal cardiac contraction and (B) mechanism of action of various cardiac inotropic agents. AC, adenyl cyclase; AMP, adenosine
monophosphate; ATP, adenosine triphosphate; CA, calcium; cAMP, cyclic adenosine monophosphate; PDE, phosphodiesterase; LTCC, L-type
Ca2+ channels; PKA, protein kinase A; SERCA, sarcoplasmic reticulum calcium pump.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Mechanism of action of key inotropes and their impact on intermediate outcome measures in heart failure
Inotrope Mechanism of action Impact on intermediate outcomes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amrinone PDE3i Improvement in haemodynamics and exercise
capacity9,10,20,21
Enoximone PDE3i Improvement in haemodynamics11,14
Milrinone PDE3i Improved haemodynamics and functional status13,22,23
Xamoterol 𝛽1-selective partial agonist Improved haemodynamics and functional status
24
Dobutamine 𝛽1 and 𝛽2 agonist Improved haemodynamics
25
Flosequinan Peripheral arteriolar and venous vasodilator Improved haemodynamics, decreased natriuretic peptides,
improved symptoms and exercise tolerance26
Pimobendan Calcium sensitizer and selective PDE3i Improved functional status and reduced hospitalization19,27
Levosimendan KATP channel activator, calcium sensitizer, PDE3i Improved haemodynamics, decreased natriuretic peptides,
improved patient symptoms15–18,28
Ibopamine DA-1 and DA-2 receptor activation: renal and peripheral
vasodilatation
↓Neurohormones, improved functional status29
Vesnarinone ↑Sodium–calcium exchange, mild PDE3i Improved haemodynamics and exercise capacity12,30
Omecamtiv mecarbil Potentiates effects of myosin on actin ↑SET, improved ventricular function (↑SV, ↑LVEF),
ventricular dimensions (↓LVEDV, ↓LVESV), decreased
neurohormonal activation (↓heart rate), ↓NT-proBNP31
Istaroxime Stimulates SERCA2a and inhibits Na-K ATPase ↓PCWP, ↑CO, ↓LVEDV32
SERCA2a gene Restoration of SERCA2a function to improve calcium
release and reuptake from the SR
Improved functional status, ↓NT-proBNP, ↑LVEF33
CO, cardiac output; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; PCWP, pulmonary capillary wedge pressure; PDE3i, phosphodiesterase 3 inhibitor; SERCA2a, sarcoplasmic reticulum Ca2+-ATPase; SET, systolic
ejection time; SR, sarcoplasmic reticulum; SV, stroke volume.
Another agent which is also a potent PDE inhibitor, pimobendan,
significantly increased exercise duration, peak oxygen uptake, and
quality of life in patients with heart failure (Table 1).9,13,14,17–33
After a significant hiatus in the development of positive inotropes
for heart failure, further mechanistic targets were developed in
the 2000s. Pharmacological and gene therapy approaches were
directed at a key enzyme responsible for myocardial calcium
homeostasis that is downregulated in heart failure: sarcoplasmic
reticulum Ca2+-ATPase (SERCA2a). Correction of this deficiency
improved the function of impaired cardiomyocytes in vitro and
prolonged survival in vivo when tested on experimental models
of heart failure. In human subjects, intracoronary infusion of a
SERCA2a cDNA vector did not lead to a difference in heart failure
exacerbations.34 This might have been due to inefficient genetic
transfer; istaroxime, an intravenous inotrope, also works by
stimulating SERCA2a whilst also inhibiting the sodium–potassium
ATPase pump, potentially bypassing this issue.35,36 This dual
mechanism of action results in istaroxime having both inotropic
action, by allowing the accumulation of cytosolic calcium during
contraction, as well as having a lusitropic effect (improvement in
diastolic relaxation) by sequestering calcium during relaxation.
Results from animal experiments with istaroxime corroborated
this favourable mechanistic profile by showing increased inotropy
and accelerated relaxation without associated increased energy
consumption or arrhythmias.37
Inotrope therapy expanded further with the development of
agents that act directly on the actinomyosin cross-bridge. Ome-
camtiv mecarbil is the first-in-class agent for this category with a ..
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.. unique mechanism of action that makes it distinct from traditional
inotropes, in so much as it does not clearly fit this categoriza-
tion. It works by selectively binding to the S1 domain of cardiac
myosin, the main component of the thick sarcomeric filament, sta-
bilizing the pre-powerstroke state, leading to increased effective
myosin interaction with actin causing increased and prolonged con-
tractile force without increasing left ventricular filling pressure or
intracellular calcium content38,39 (Figure 2). Via this mechanism,
omecamtiv mecarbil increases the efficiency and performance of
the cardiac contractile apparatus. Early phase clinical studies have
shown that omecamtiv mecarbil increases LVEF, stroke volume, sys-
tolic ejection time, and decreases left ventricular end-diastolic and
end-systolic volumes.31
Results from clinical trials
Clinical trials of inotropes in heart failure have reinforced an
important lesson: whereas short-term surrogate endpoints such
as haemodynamics might improve with these therapies, this does
not necessarily translate into improvements in mortality. Inotropic
therapies to date have failed to improve ‘hard’ clinical outcomes
in heart failure, and the majority resulted in worse outcomes
(Table 2).14,32,34,40–57 Furthermore, only a subset of results from
trials investigating inotropes have been published, some many
years after the results were presented, and the primary data are
not available for analysis making a meticulous post-mortem of
disappointing prior results challenging.58,59
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Mechanism of action of omecamtiv mecarbil. ADP, adenosine diphosphate; ATP, adenosine triphosphate.
Adrenergic agents
Dobutamine was the first inotrope developed, but it has never been
formally compared with placebo in a clinical trial of patients with
heart failure. Its safety and efficacy were extrapolated from a sub-
group analysis of the Flolan International Randomized Survival Trial
(FIRST) study (published in 1997) that randomized 471 patients
with New York Heart Association (NYHA) class IIIB–IV symp-
toms to epoprostenol (prostacyclin) infusion vs. standard care.60
The trial was terminated early because of a strong trend toward
decreased survival among patients treated with epoprostenol.
Furthermore, epoprostenol therapy was not associated with
improvement in distance walked or quality of life measures. A
post-hoc analysis of this study compared 80 patients who were
treated with and without dobutamine at time of randomization.
The investigators found that dobutamine use was associated with
a higher 6-month mortality rate. While the increased mortality
persisted despite adjustment for baseline differences, the dobu-
tamine group notably included a sicker population, which may
have influenced the results. Other studies where intermittent
dobutamine infusion was used showed no improvement in clinical
class and increased mortality.61 This has led to the conclusion
that dobutamine use might lead to harm in patients with advanced
symptomatic heart failure.46
Xamoterol, a 𝛽1-selective partial adrenergic agonist, demon-
strated favourable haemodynamic and symptomatic improvement
in initial studies but was found to have more than a twofold
increased risk of death over placebo when evaluated in a large
randomized trial published in 1990. Specifically, 516 patients with
NYHA class III–IV symptoms despite treatment with diuretics ..
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. and angiotensin-converting enzyme inhibitors were randomized
in a 2:1 fashion to xamoterol 200mg or placebo twice daily for
13weeks. There was no difference between the treatments in
exercise duration or total work done. Compared to a rate of 3.7%
in the placebo arm, 9.1% of patients in the xamoterol group died
within 100 days of randomization.41 Ibopamine is an oral dopamin-
ergic agonist, which also has some 𝛼-adrenergic and 𝛽-adrenergic
activity.62 It was shown to improve heart failure symptoms in the
Prospective Randomized Study of Ibopamine on Mortality and Effi-
cacy (PRIME).63 This led to the PRIME II trial that was stopped
early because of a 26% increase in mortality among patients in the
ibopamine group.44
Phosphodiesterase inhibitors
Two landmark trials examined the benefit of milrinone therapy
in heart failure. The Prospective Randomized Milrinone Survival
Evaluation (PROMISE), published in 1991, randomized 1088 ambu-
latory patients with heart failure with reduced ejection fraction and
NYHA class III–IV symptoms to 40mg of oral milrinone daily vs.
placebo and followed the patients for a median of 6.1 months.42
Patients on chronic heart failure were on contemporaneous
therapy of digoxin, diuretics, and angiotensin-converting enzyme
inhibitors. As compared with placebo, milrinone therapy was asso-
ciated with a 28% increase in all-cause mortality and a 34% increase
in cardiovascular mortality. Patients treated with milrinone also had
more hospitalizations and more serious adverse reactions includ-
ing hypotension and syncope. The investigators concluded that
‘despite its beneficial haemodynamic actions, long-term therapy with
oral milrinone increases the morbidity and mortality of patients with
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Results of clinical trials involving positive inotropes in heart failure with reduced ejection fraction
Clinical trial Comparator groups Year No. patients Key inclusion criteria Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amrinone
Multicenter Trial40
Amrinone vs. placebo 1985 99 NYHA class III–IV, LVEF ≤ 40% ↑ Adverse events
Xamoterol in Severe
Heart Failure41
Xamoterol vs.
placebo
1990 516 LVEF < 35%, NYHA class III–IV ↑ Morbidity
PROMISE42 Milrinone vs. placebo 1991 1008 LVEF ≤ 35%, NYHA class III–IV ↑ Morbidity and mortality
PICO43 Pimobendan 1996 317 NYHA class II–III, LVEF ≤ 45% ↑ Exercise tolerance,
↑ mortality
PRIME II44 Ibopamine 1997 1906 NYHA class III–IV, LVEF < 35% ↑ Mortality
VEST45 Vesnarinone 1998 3833 LVEF ≤ 30%, NYHA class III–IV Dose-dependent ↑mortality
(potentially arrhythmias)
FIRST46 Dobutamine 1999 471 NYHA class IIIB–IV; LVEF < 30% ↑ Mortality
DICE47 Intermittent
dobutamine vs.
placebo
1999 38 NYHA class III–IV, cardiac index
≤2.2 L/min/m2, and LVEF ≤ 30%
No improvement in functional
status
OPTIME-CHF48 Milrinone 2002 951 ADHF with LVEF < 40% ↑ Adverse events, equivalent
mortality
LIDO49 Levosimendan vs.
dobutamine
2002 203 ADHF with LVEF < 35%,
CI< 2.5 L/min/m2,
PCWP >15mmHg
↑ Haemodynamics,
↓ mortality with levosimendan
RUSSLAN50 Levosimendan vs.
placebo
2002 504 LV failure complicating AMI Low-dose levosimendan reduced
the risk of worsening HF
SURVIVE51 Levosimendan vs.
dobutamine
2007 1327 ADHF with LVEF ≤ 30% ↓ BNP with levosimendan but no
impact on clinical outcomes
EMOTE52 Enoximone 2007 201 NYHA class IV, inotrope
dependence, LVEF ≤ 25%
No difference is ability to wean
patients off inotropes at 30 days
Enoximone Clinical
Trials Program14,53
Enoximone 2009 1854 NYHA class III–IV, LVEF ≤ 35%
(two trials)
No difference in mortality, CV
hospitalizations, 6MWD, patient
global assessment
HORIZON-HF32 Istaroxime 2008 120 ADHF with LVEF ≤ 35% ↓ PCWP, ↑ SBP, and ↓ diastolic
stiffness
CUPID 234 SERCA2a gene 2016 250 Chronic HF, NYHA class II–III,
LVEF ≤ 35%, NT-proBNP
> 1200 pg/mLa
No difference in time to recurrent
events
REVIVE54 Levosimendan 2013 700 ADHF with LVEF ≤ 35% ↓ HF symptoms, ↑ risk of adverse
CV events and 14-day mortality
ATOMIC-AHF55 Omecamtiv mecarbil 2016 606 ADHF with LVEF ≤ 40%, BNP
> 400 pg/mL or NT-proBNP
> 1600 pg/mLa
No difference in dyspnoea
endpoint, ↑ SET, ↓ LVESD,
↑ troponin
COSMIC-HF56 Omecamtiv mecarbil 2016 448 Chronic HF, NYHA class II–III,
LVEF ≤ 40%, NT-proBNP
≥ 200 pg/mLa
↑ SET, ↑ SV, ↓ LVESD, ↓ LVEDD,
↓ NT-proBNP
PROFILE57 Flosequinan 2017 2354 NYHA class III–IV, LVEF ≤ 35% ↑ Exercise tolerance,
↑ mortality
6MWD, 6-min walk distance; ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; BNP, B-type natriuretic peptide; CI, cardiac index; CV, cardiovascular;
HF, heart failure; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; SBP, systolic blood pressure; SET,
systolic ejection time; SV, stroke volume.
aDifferent cut-points for atrial fibrillation.
severe chronic heart failure’. The Outcomes of a Prospective Trial
of Intravenous Milrinone for Exacerbations of Chronic Heart Fail-
ure (OPTIME-CHF) trial was published in 2002 and randomized
951 patients with acute exacerbations of chronic heart failure to a
48 h infusion of either milrinone (0.5 μg/kg/min initially) or saline ..
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. placebo.48 Results did not differ significantly in either mortality
or readmission endpoints. However, those randomized to milri-
none experienced more clinically relevant hypotension and atrial
arrhythmias and patients with ischaemic heart disease had signif-
icantly greater in-hospital mortality with milrinone. Comparable
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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results regarding mortality were observed with enoximone in a
smaller trial of 102 patients.64
Vesnarinone, an oral agent with PDE inhibition that also prolongs
the sodium ion channel opening, was initially seen as promising
because of its weak PDE inhibiting and novel ion channel proper-
ties. The large-scale trial of vesnarinone in heart failure tested two
doses of vesnarinone, 60mg or 120mg, vs. placebo.30 The 120mg
arm was discontinued early because of a twofold mortality increase
over placebo. The trial continued with the 60mg arm vs. placebo
and showed a surprising 62% decrease in the relative risk of death in
patients randomized to vesnarinone treatment. As a result of the
small number of clinical endpoints in the initial trial and concern
about the possibility of neutropenia from vesnarinone, the larger
Vesnarinone Trial (VEST) was undertaken, comparing 30 or 60mg
of vesnarinone daily with placebo in ambulatory patients. Published
in 1998, this trial demonstrated a dose-dependent increase in mor-
tality with vesnarinone over placebo, primarily because of arrhyth-
mic death, and the crossover group did not respond in a similar
fashion to the initially randomized group. Of note, there was a sig-
nal towards improved quality of life in the higher dose arm, and
some suggested that patients with refractory end-stage heart fail-
ure might be willing to trade-off a slightly increased risk of mortality
for improved quality of life. However, this notion has not translated
to the bedside, as vesnarinone is not available for clinical use.45,65
Oral vasodilators with positive inotropic
properties
Flosequinan has both vasodilating and inotropic properties that are
not entirely understood but felt to be distinct from 𝛽-adrenergic
receptor agonists and PDE inhibitors.66 This agent was initially
greeted with enthusiasm based on its improvement in heart failure
symptoms and quality of life scores.67 The Prospective Randomized
Flosequinan Longevity Evaluation (PROFILE) study examined the
clinical impact of flosequinan on 2354 patients with NYHA class
III-IV heart failure and LVEF ≤ 35%. The primary outcome of the
study was all-cause mortality. The trial was terminated early due
increased mortality, and the therapy was withdrawn from the
market in 1994.57,68 Of note, results of the study were finally
published 24 years after its completion.57
Calcium sensitizers
Several large randomized controlled trials in patients with heart
failure have examined levosimendan, a calcium sensitizer with
PDE inhibitor and KATP-channel activating effects. Two sequential
trials — Randomized Multicentre Evaluation of Intravenous Lev-
osimendan Efficacy (REVIVE) I and II — aimed to first develop a
new measure of efficacy in 100 patients, then to use this measure
to evaluate levosimendan in an additional 600 patients. Patients
admitted with acute exacerbations of heart failure received
placebo or intravenous levosimendan for 24 h in addition to
standard treatment. Levosimendan provided greater degrees of
symptomatic relief but was associated with a significant increase
in mortality in the first 14 days, presumably while levosimendan
was pharmacologically active. This early mortality difference ..
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.. in events was maintained with a slightly higher risk of 90-day
all-cause mortality in the levosimendan group (15.1%) vs. controls
(11.6%).54 Levosimendan also increased atrial fibrillation and
ventricular arrhythmias. The Survival of Patients with Acute Heart
Failure in Need of Intravenous Inotropic Support (SURVIVE) study
randomized 1327 patients hospitalized for acute decompensated
heart failure to levosimendan vs. dobutamine.51 There were no
differences in either mortality or measures of patient symptoms.
Those in the dobutamine arm had a higher incidence of car-
diac failure. Of note, natriuretic peptide levels were significantly
reduced in the levosimendan arm compared with the dobutamine
arm. The PERSIST trial randomized 307 patients in NYHA class
IIIB–IV to levosimendan 1 mg once or twice daily or placebo for
at least 180 days. Levosimendan did not improve the prespecified
novel outcome measure (a patient journey composite), but there
was a suggestion that it improved some quality of life metrics and
decreased natriuretic peptide levels.69 Levosimendan use has been
approved for use in Europe for palliation on the basis of these
data. Data from registries and clinical trials have demonstrated
that this approach is safe and may improve clinical outcomes.70,71
Finally, two small studies have recently assessed the use of
intermittent levosimendan in advanced heart failure patients.
The LION-HEART (Intermittent Intravenous Levosimendan in
Ambulatory Advanced Chronic Heart Failure Patients) pilot study
randomized 69 patients to intermittent levosimendan (infusions
every 2 weeks for 12weeks) or placebo. Adverse events were
similar between groups, and those randomized to levosimendan
had lower N-terminal pro-B-type natriuretic peptide levels over
time and fewer heart failure rehospitalizations.71 Similarly, the
LAICA (Long-Term Intermittent Administration of Levosimendan
in Patients with Advanced Heart Failure) study, which has been
presented but not published, showed fewer hospitalizations with
intermittent levosimendan.72 Levosimendan is currently approved
for use in Russia and some European and South American
countries, but not in the United States.
Pimobendan, a PDE inhibitor with some calcium-sensitization
effects, was evaluated in the double-blind randomized Pimobendan
in Congestive Heart Failure (PICO) trial published in 1996.43
This multicentre European trial randomized 317 outpatients with
NYHA class II–III chronic heart failure symptoms to placebo
or pimobendan at 2.5 or 5 mg daily. Compared with placebo,
both doses of pimobendan improved exercise duration by 6%
after 24weeks of treatment, but did not improve quality of life
measures or peak oxygen uptake. More importantly, pimobendan
treatment was associated with an insignificant but worrisome
1.8-fold increased risk of all-cause mortality, which resulted in
the discontinuation of its clinical development. However, market
authorization was granted in Japan where the observed mortality
with its use has been noted to be lower than expected, potentially
due to concomitant 𝛽-blocker usage. Also, an oral formulation is
used worldwide in veterinary medicine.43,73,74
Myosin activators
Omecamtiv mercarbil has been evaluated in two relatively large
patient populations of acute and chronic heart failure in phase 2
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studies. The Chronic Oral Study of Myosin Activation to Increase
Contractility in Heart Failure (COSMIC-HF) trial randomized 448
outpatients with well-controlled heart failure (NYHA class II–III
and LVEF ≤ 40%) to one of three groups: fixed-dose, pharma-
cokinetic titration, or placebo for 20weeks.56 The study met its
primary pharmacokinetic endpoint and the investigators noted
an improvement in all of the pre-specified secondary efficacy
parameters: systolic ejection time and stroke volume increased
whereas left ventricular end-systolic and end-diastolic dimensions,
heart rate and natriuretic peptide levels decreased favourably in
the active treatment arm. Adverse clinical events in omecamtiv
mecarbil-treated arms were similar to placebo. The Acute Treat-
ment with Omecamtiv Mecarbil to Increase Contractility in Acute
Heart Failure (ATOMIC-AHF) trial randomized 613 patients with
acute decompensated heart failure and LVEF ≤ 40% to omecamtiv
mecarbil vs. placebo for 48 h during their hospitalization.55 There
were no differences in the primary efficacy endpoint of improve-
ment in dyspnoea in the entire cohort, with a signal for bene-
fit in the highest dose group. Of the 89 patients studied in the
echocardiographic subgroup, increases in left ventricular systolic
ejection time and decreases in left ventricular end-systolic dimen-
sion were observed in a concentration-dependent pattern. The
finding that troponin levels at 48 h tended to be slightly higher in
those patients that received omecamtiv mecarbil is of unresolved
mechanism or clinical significance despite much deliberation.75–78
The ongoing 8000 patient Global Approach to Lowering Adverse
Cardiac Outcomes Through Improving Contractility in Heart Fail-
ure (GALACTIC-HF; NCT02929329) trial is evaluating the effect
of chronic oral omecamtiv mecarbil on cardiovascular mortality
and heart failure events in patients with heart failure with reduced
ejection fraction.
Sarcoplasmic reticulum Ca2+-ATPase
(SERCA2a) modulation
For some time, it has been clear that myocardial SERCA2a activity
is reduced in patients with heart failure, and that restoration
of its activity improves myocardial function. As detailed above,
istaroxime is an intravenous inotrope that stimulates SERCA2a
by inhibiting the sodium–potassium ATPase pump. In the phase 2
Hemodynamic, Echocardiographic, and Neurohormonal Effects of
Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a
Randomized Controlled Trial in Patients Hospitalized with Heart
Failure (HORIZON-HF) trial, istaroxime showed that it lowered
pulmonary capillary wedge pressure, increased cardiac output,
and decreased left ventricular end-diastolic volume.32 A later pilot
study [Calcium Upregulation by Percutaneous Administration of
Gene Therapy in Cardiac Disease (CUPID 1)] demonstrated ben-
eficial effects of SERCA2a gene therapy in patients with advanced
heart failure.33 This led to the CUPID 2 trial, which randomized
250 symptomatic heart failure patients with LVEF < 35% to receive
a single intracoronary infusion of AAV1/SERCA2a or placebo.34
Results of the trial were published in 2016 and did not find any
benefit of SERCA2a treatment on the primary outcome, defined
as time to recurrent events (hospital admission because of heart
failure or ambulatory treatment for worsening heart failure). ..
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.. One potential reason for failure of this approach is felt to be
inefficient gene transfer, and other targets for this pathway are
being evaluated.
Why have prior inotrope trials
in chronic heart failure been
negative?
The development of positive inotropic agents for chronic heart fail-
ure with reduced ejection fraction has followed a recurring theme
despite testing of a variety of agents that targeted diverse molecular
pathways: improvements in surrogate measures of cardiac improve-
ment do not necessarily translate into reduction in clinical events.
Some reasons for this are likely to be compound specific, but sev-
eral themes have emerged from the experience. Of note, these
do not apply to the use of inotropic therapies for acute cardio-
genic shock, where there are compelling data in support of bridging
patients to stability.
Improvements in short-term
haemodynamics may not translate into
longer-term mortality and morbidity
benefits
The haemodynamic model of heart failure suggest that reversing
left ventricular systolic function will make patients feel better and
live longer.79 In line with this concept, haemodynamic assessments
have been the entryway whereby dozens of inotropic agents have
progressed to phase 3 clinical trials. Invariably, drugs that improved
haemodynamics via a variety of mechanisms with documented
increases of cardiac performance and improvements in blood flow
to the peripheral organs failed to show clinical benefit in large
clinical trials. Indeed, most were even associated with a heightened
risk of death.80
The lack of a direct relationship between interventions that led
to short-term haemodynamic improvements and clinical efficacy is
not restricted to inotropes. Nesiritide, a recombinant human brain
natriuretic peptide, was approved for clinical use based on small
studies showing reductions in filling pressures, but subsequent
trials showed no evidence of therapeutic efficacy.81 Furthermore,
the landmark Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial
demonstrated that haemodynamic-guided therapies in heart failure
did not improve clinical outcomes, among patients in whom there
was equipoise about use of these data.82 Finally, the negative
impact of 𝛽-blockade on these indices prevented their clinical use
for decades.83
Therefore, the aggregate data suggest that short-range haemo-
dynamic endpoints might be misleading as surrogate measures
for long-term morbidity and mortality benefits from inotropes,
with the caveat that it is unknown as to what combination
of haemodynamic parameters constitute adequate improve-
ment, and prior studies might have erred on the side of higher
doses of inotropes to achieve larger than needed changes in
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haemodynamics. Additionally, it is entirely plausible that tempo-
rary treatment with an effective therapy will not translate into
improvement in long-term clinical outcomes.
Benefit from inotropes might only be
restricted to sub-phenotypes of heart
failure
Heart failure is not a singular disease. Rather, it is a syndrome that
likely comprises several diseases with unique underlying mecha-
nisms and trajectories.84–86 Moreover, classification systems based
on a century old assessment of functional status (NYHA class),
or LVEF cut-points are fundamentally dissociated from both mech-
anistic and clinical actuality.87 Whereas trials of neurohormonal
blockade have succeeded despite these constraints, we might now
need to identify specific subgroups of the syndrome that respond
favoorably to inotropes, in a manner analogous to cardiac resyn-
chronization therapy. Thus far, all clinical trials of positive inotropes
in heart failure have been anchored in broad measures of disease,
leading to overly simplified and often inaccurate assumptions about
how these therapies might help patients.88 The significant draw-
backs of this approach were demonstrated in a post-hoc analysis
of the OPTIME-CHF trial that showed a substantial impact of heart
failure aetiology (ischaemic vs. non-ischaemic) on clinical outcomes
with milrinone, with harm seen in patients with ischaemic disease.89
In a manner analogous to how a therapy would not be tested gener-
ically for lung cancer or anaemia, we would be well served by
testing future inotropes in a sub-population of the syndrome (e.g.
non-ischaemic dilated cardiomyopathy) that might benefit from the
therapy. While there is a dearth of relevant data to approve ther-
apies based on subtypes of heart failure, one population that may
benefit are those with advanced, chronic heart failure and low out-
put. Alternatively, inotropes with potentially anti-remodelling prop-
erties, such as omecamtiv mecarbil,56 could potentially be used at
an earlier stage.
The mechanism and dosage of inotropic
agents can cause adverse effects
There is a possibility that the adverse effects of inotropic agents on
myocardial energetics and intracellular calcium could explain the
results of prior trials: by increasing energy consumption and lead-
ing to exhaustion of the energy stores, these agents could promote
pump failure as well as ventricular arrhythmias via dysfunctional
calcium cycling. In fact, the negative long-term impact of cate-
cholamines on the heart, and the beneficial impact of 𝛽-blockade,
has been demonstrated in several landmark studies.90 Additionally,
data suggest that drugs acting via cAMP modulation lead to adverse
effects in the long term by causing desensitization of the contractile
apparatus to calcium, disturbing intracellular calcium homeostasis,
causing ventricular arrhythmias, and disrupting lusitropy. Studies
have shown that left ventricular function deteriorates to below
pre-treatment levels after withdrawal of inotropes, demonstrating
that the therapy accelerates ventricular dysfunction.91 It is con-
ceivable that 𝛽-adrenergic blocking agents might have prevented ..
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.. this deterioration of ventricular function, but their usage was infre-
quent during most clinical trials.
An intriguing corollary to the notion that the inotropic effects
of drugs might explain their negative impact on clinical outcomes
is that many clinical trials studying these agents aimed to maximize
their positive haemodynamic effects and used very high doses for
this purpose. Similar to the deleterious effects of very high doses of
digoxin, it is quite possible that by chasing the wrong intermediate
measures of heart failure, prior studies drove up the risk of myocar-
dial toxicity and shifted the risk–benefit equation in the wrong
direction.80 This was articulated by Dr. Milton Packer in a perspec-
tive article published in a 1993 issue of JACC — in the aftermath
of a large number of negative inotrope trials — where he con-
cluded: ‘The belief that positive inotropic agents for heart failure should
be developed at inotropic doses may have been the primary factor for the
controversy that has surrounded these drugs for the last 200 years’.80
Medical treatment of patients in prior
trials did not protect them from sudden
cardiac death
As displayed in Table 3,14,41–46,48,53,54,56,57 most of the land-
mark trials that tested positive inotropes in heart failure had
very low usage of key therapies — 𝛽-blockers and implantable
cardioverter-defibrillators (ICDs) — that are known to protect
heart failure patients against sudden cardiac death, the mode of
death most commonly provoked by these medications. In fact,
many of these trials listed 𝛽-blocker use as an exclusion criterion as
they occurred prior to when these medications were found to be
of benefit in heart failure. Whereas the actual prevalence of ICD
use is unclear from most of the published manuscripts, it generally
occurred prior to the landmark trials showing benefit of these
devices for primary and secondary prevention of sudden death
in heart failure with reduced ejection fraction.92 Furthermore,
usage of additional neurohormonal agents was low in these trials,
potentially leading to even less protection from the adverse effects
of adverse remodelling. Finally, a large portion of patients in
positive inotrope trials were on concomitant digoxin, often on
higher doses than are currently considered therapeutic. Given the
mechanistic intersections between digoxin and cardiac inotropes,
it is plausible that concomitant usage might have had a negative
synergistic effect.93 These have been proposed as reasons as to
why contemporary outcomes from inotrope usage are better
that those seen in trials.92,93 In addition, a recent meta-analysis
has suggested that ambulatory inotrope infusions in advanced
stage D heart failure may improve NYHA functional class without
negatively impacting survival.94
Increasing contractility rather than
improving efficiency
At the core of arguments about whether it is worth developing
positive inotropes for heart failure is an unresolved debate about
whether stimulating the failing heart is truly beneficial.80 It is
possible that decreased contractility is a compensatory response
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Use of key contemporary heart failure therapeutics in prior clinical trials of positive inotropes
Study Therapy Year IHD Beta-blocker ACEi/ARB ICD Digoxin Risk of death
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Xamoterol in Severe
Heart Failure41
Xamoterol vs. placebo 1990 60% Excluded > 80% Unknown 53% ↑ Risk of all-cause mortality with
xamoterol
PROMISE42 Milrinone vs. placebo 1991 54% Excluded Yes, unknown Unknown Yes, unknown 28% increase in all-cause
mortality, 34% increase in CV
mortality
PICO43 Pimobendan vs. placebo 1996 70% Excluded Yes, 100% Excluded 59% NS increase in risk of all-cause
mortality
PRIME II44 Ibopamine vs. placebo 1997 59% Unknown, but
low
92% Unknown 64% 26% increase in all-cause
mortality
VEST45 Vesnarinone vs. placebo 1998 60% Excluded 90% Excluded Unknown 21% increase in all-cause
mortality with vesnarinone
FIRST46 Epoprostenol vs. placebo 1999 67% Unknown, but
low
84% Unknown Yes, Unknown ↑ Risk with epoprostenol infusion
(trial stopped), ↑ risk in DBA
subgroup
OPTIME-CHF48 Milrinone vs. placebo 2002 51% 22% 82% Unknown 78% ↔ No difference compared with
placebo
REVIVE54 Levosimendan vs.
placebo
2004 53% 68% 77% Unknown 52% ↔ No difference compared with
placebo
Enoximone Clinical
Trials Program14,53
Enoximone vs. placebo 2009 52% 83% 98% 21% 69% ↔ No difference compared with
placebo
COSMIC-HF56 Omecamtiv mecarbil vs.
placebo
2016 98% 94% 62% 20% Phase 2 study
PROFILE57 Flosequinan vs. placebo 2017 67% <4% Yes, 100% Unknown Yes, Unknown 39% increase in all-cause
mortality
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CV, cardiovascular; ICD, implantable cardioverter-defibrillator; IHD, ischaemic heart disease.
aimed at preventing disease progression. If this is the case, then
positive inotropes might improve cardiac performance in the short
term but are likely to increase the risk of pump failure when
used in a chronic manner. However, as our clinical experience
with cardiac resynchronization therapy has shown, focusing on
the efficiency rather than simply the contractility of the heart
has the potential to both improve patient symptoms and clinical
outcomes.95 Since heart failure is a state of dysfunctional cardiac
energetics — the so-called ‘engine out of fuel’ — it is possible
that biomarkers including metabolic assessments could serve as
surrogate measures of whether a positive inotrope is helping or
hindering the heart efficiency.96 Furthermore, interventions aimed
at increasing high energy phosphate production have resulted in
a safe and significant effect on cardiac contractility and exercise
capacity.97 In future clinical trials, patients who are likely to benefit
from positive inotropy might be identified via a run-in period with
intensive biomarker and imaging assessments that track well with
clinical outcomes (Figure 3).
Why is there a disconnect
between trial results and clinical
use of inotropes?
Any practicing heart failure clinician would strongly argue that
the two clinically available inotropes for stage D heart fail-
ure — milrinone and dobutamine — are essential tools in their
therapeutic armamentarium. Their clinical use reflects this fact
whereas exact numbers on a national level are unknown. Stud-
ies have approximated that more than 6% of patients admitted ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. with heart failure are placed on intravenous inotropes and in 2014
Medicare spent $243 million for home milrinone and $3.8 mil-
lion for home dobutamine infusions.98 Likely because of the rapidly
increasing prevalence of end-stage heart failure, with a large per-
centage of patients either medically ineligible for or opting not to
undergo heart transplantation or implantation of left ventricular
assist devices, the usage of inotropes is increasing rapidly. Of note,
this is occurring despite the clear lack of data supporting the ben-
efit of chronic inotropic usage in heart failure and robust evidence
suggesting the potential for harm. Furthermore, it also goes against
the Food and Drug Administration (FDA) regulatory label for both
milrinone and dobutamine that has approved their use for ‘inotropic
support in the short-term treatment of patients with cardiac decompen-
sation due to depressed contractility resulting either from organic heart
disease or from cardiac surgical procedures’. In keeping with the data,
the label specifically mentions that there are no data for treatment
with these agents for more than 48 h — the primary way they are
currently used in the clinical setting:
‘Experience with intravenous dobutamine in controlled trials does
not extend beyond 48 h of repeated boluses and/or continu-
ous infusions. Whether given orally, continuously intravenously,
or intermittently intravenously, neither dobutamine nor any other
cAMP-dependent inotrope has been shown in controlled trials
to be safe or effective in the long-term treatment of congestive
heart failure. In controlled trials of chronic oral therapy with var-
ious such agents, symptoms were not consistently alleviated, and
the cAMP-dependent inotropes were consistently associated with
increased risks of hospitalization and death. Patients with NYHA
class IV symptoms appeared to be at particular risk.’
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Figure 3 Summary of trials that evaluated neurohormonal antagonist and device therapies, and positive inotropes for heart failure. CRT,
cardiac resynchronization therapy. [Correction added on 29 August 2019, after first online publication: the text under 2014 PARADIGM-HF
has been corrected.]
Why is use of these agents so common? Clearly, there is a large
and rapidly growing population of patients who might benefit from
these medications and were not represented in prior clinical trials.
At the current time, however, several questions about inotrope
usage in stage D heart failure remain unanswered. We do not
know: (i) how to identify the patient populations who will benefit
from these therapies, (ii) whether the benefits are purely symp-
tomatic or can extend to hard clinical outcomes, (iii) how to dose
either inotropes or concomitant neurohormonal therapies, and (iv)
how inotrope use can fit into the patient-centred decision- mak-
ing regarding complex therapies for end-stage heart failure. The
epidemiologic insignificance of heart transplantation as a thera-
peutic intervention and the cost and morbidity associated with
ventricular assist devices create an enormous potential for posi-
tive inotropic therapies for advanced heart failure. Currently there
is a large chasm between clinical practice and academic under-
standing of these agents. Addressing these questions are likely to
bring us closer to using and developing cardiac inotropes that meet
patient-specific needs without causing disproportionate harm.
What is the future of inotropes
in heart failure?
It is plausible to suggest that if prior clinical trials of positive
inotropes were repeated today, more judicious study designs and
a patient population on 𝛽-blockers with ICDs would yield very
different results. Indeed, if the symptomatic benefits of inotropic
agents — in particular, those with oral formulations — could be ..
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. extracted without undesirable clinical outcomes, it would present
a much needed therapeutic option to a growing population of
patients with heart failure in whom the cost and burden of alterna-
tives such as mechanical circulatory support and cardiac transplan-
tation is undesirable. Therefore, we propose some considerations
for future trials testing positive inotropes in heart failure (Figure 4).
Enrich for subgroups of patients most
likely to benefit
There is evidence to suggest that patients on neurohormonal
antagonists — particularly 𝛽-blockers — and with ICDs who are
started on positive cardiac inotropes may have much better survival
than seen in prior clinical trials. Therefore, enriching future clinical
trials with such patients may allow for boosting the risk–reward
ratio.
Use biomarkers and imaging in trial
design and execution
In trials involving therapies that have potential cardiotoxicity, it
might be beneficial to have a run-in period with intensive advanced
cardiac imaging measures and a comprehensive list of cardiac and
cardiorenal biomarkers that track with clinical outcomes and may
allow for early identification of patients who might not benefit from
a positive inotrope.99 Of note, no clinical trial of inotropes has
used this approach to date, but it is rather common in oncology,
despite the shared goal of balancing beneficial and adverse effects
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Considerations for future trials testing positive inotropes in heart failure. ICD, implantable cardioverter-defibrillator; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association.
of therapies. With this approach, we might exclude patients who
have elevations in cardiac injury markers, for example, in a manner
analogous to the Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart
Failure (PARADIGM-HF) trial that used a run-in period to exclude
patients whose blood pressure was intolerant of the highest doses
of sacubitril/valsartan.100
Evaluate efficacy based on factors
beyond haemodynamics
Whereas haemodynamic measurements are the foundation on
which contemporary understanding of heart failure is based, their
value for either tailoring or predicting the efficacy of therapeutics
has been repeatedly diminished by objective data. Indeed, showing
haemodynamic improvements was the rite of passage for almost
every positive cardiac inotrope that did not show clinical benefit in
a phase 3 clinical trial. Since invasive haemodynamics are onerous
to obtain and offer a simplistic snapshot of the cardiac impact
of therapeutic interventions, their measurement should not be
considered essential in the path to clinical development of a cardiac
inotrope.
Collect detailed data on functional status
and quality of life
A strong case could be made for the clinical approval of a positive
inotrope that improved functional status and quality of life in heart ..
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.. failure patients but had a neutral impact on mortality. Nonetheless,
despite the widespread use of inotropes for relief of symptoms, we
lack even basic information on these metrics. Prior trials neglected
this vital information, choosing instead to focus heavily on physio-
logical and mortality data. Now that heart failure-specific quality of
life questionnaires have been developed and validated, future trials
should be designed around outcomes that matter to heart failure
patients with a focus on the ‘patient journey’ rather than an inordi-
nate focus only on the risk of death or hospitalization.101 The use
of mobile health technologies can allow for this to be done in a
cheaper and more streamlined fashion while concurrently collect-
ing granular data on individual patients.102 Importantly, the FDA has
indicated that approvability of inotrope therapies could be based on
improvement in symptoms even if no clear adversity in survival is
found. The lack of such approvals is largely a function of deficient
data rather than regulatory philosophy.
Conclusions
Current pharmacological therapies for heart failure with reduced
ejection fraction are largely either repurposed anti-hypertensives
that blunt overactivation of the neurohormonal system or diuretics
that decrease congestion. They do not address the symptoms of
heart failure that result from reductions in cardiac output and
reserve. Over the last few decades, numerous attempts have been
made to develop and test positive cardiac inotropes that improve
cardiac haemodynamics but clinical trials have shown these agents
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to be harmful to patients. As a result, no positive inotrope is
currently approved for long-term use in heart failure. By revisiting
prior clinical trials and attempting to understand why they ended
in a disappointing fashion, we propose a framework for future
trials of such agents that might improve chances for success.
With a rapidly growing population of patients with advanced heart
failure, the epidemiologic insignificance of heart transplantation
as a therapeutic intervention, and both the cost and morbidity
associated with ventricular assist devices, there is an enormous
potential for positive inotropic therapies to impact the outcomes
that matter most to patients.
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